MarketsandMarkets Presents Patient Derived Xenograft/PDX Models Market worth 167.6 Million USD by 2022 http://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html
The report "Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022“. Browse: 44market data tables,34figures , 148pages And in-depth TOC on “Patient Derived Xenograft/PDX Models Market” Get The PDF Brochure For This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=121598251 The PDX models market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%. http://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html
The growth of the overall Patient Derived Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. In the coming years, North America is expected to account for the largest share of the global market. Base year considered for the report is 2016 and the forecast period includes 2017–2022. Drivers: Growing Demand for Personalized Medicine Continuous Support for Cancer Research From Public as Well as Private Sector Growth in the Number of Pharmaceutical R&D Activities Opportunity: Rising Demand for Humanized PDX Models Request a sample of the report: http://www.marketsandmarkets.com/requestsample.asp?id=121598251 http://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html
Industry Insights: On the basis of tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe. Based on application, the PDX models market is further segmented into the preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research. http://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html
On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. • Target Audience: • Mice/rat models and service companies and distributors • Animal care product manufacturers and suppliers • Out–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology) • In–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology) • Industry Leaders: • The various players in the PDX models market include Crown Bioscience Inc. (US), WuXiAppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-BuchGmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and ExploraBioLabs (US).
About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. http://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html
Contact Us Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: email@example.comMarketsandMarkets Bloghttp://www.marketsandmarkets.comhttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets